Clinical characteristics of patients at time of study
Case . | Age/sex . | Diagnosis . | Stage . | Disease status . | Bone marrow involvement . | Previous chemotherapy . | Previous radiotherapy . | Splenectomy . | Time from last treatment, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 25/F | HL | IIA | Relapse | No | EBVD × 3 | STNI | No | 6 |
| 2 | 34/F | HL | IIBx | Relapse | No | VEBEP × 8 | Mantle | No | 24 |
| 3 | 57/M | HL | IVB | Relapse | Yes | VEBEP × 8 | STNI | No | 36 |
| 4 | 32/M | HL | IBx | Relapse | No | MOPP/ABVD × 6 | Mediastinum | No | 18 |
| 5 | 42/F | HL | IIBx | Refractory | No | ABVD × 7 | — | No | 1 |
| 6 | 57/F | HL | IVAx | Refractory | Yes | EBVD × 8 | — | No | 1 |
| 7 | 45/F | HL | IVA | Relapse | No | ABVD × 8 | Para-aortic | No | 12 |
| 8 | 19/F | HL | IIB | Relapse | No | ABVD × 7 | Mantle | No | 12 |
| 9 | 60/F | FL | IVA | Relapse | Yes | Fludarabine × 6 DHAP × 1 | Para-aortic | No | 1 |
| 10 | 47/F | FL | IVA | Relapse | No | CVP × 8 2CdA × 7 | — | Yes | 1 |
| 11 | 59/M | DLBCL | IVA | Relapse | No | Fludarabine × 10 | — | No | 10 |
| 12 | 57/F | DLBCL | IVB | Relapse | No | CHOP × 6 | — | No | 8 |
| 13 | 67/M | MM | IIIA | PR | Yes | VAD × 2 DT-PACE × 1 | — | No | 1 |
| 14 | 52/M | t-AML | — | CR | No | BEP × 3 FLAG-Ida × 1 | Para-aortic | No | 2 |
| 15 | 53/F | t-AML | — | CR | No | MOPP/ABVD × 8 VEBEP × 8 CBDCA × 8 FLAG-Ida × 1 | STNI | Yes | 2 |
| 16 | 58/F | t-AML | — | CR | No | FLAG-Ida × 1 | STNI | Yes | 2 |
Case . | Age/sex . | Diagnosis . | Stage . | Disease status . | Bone marrow involvement . | Previous chemotherapy . | Previous radiotherapy . | Splenectomy . | Time from last treatment, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 25/F | HL | IIA | Relapse | No | EBVD × 3 | STNI | No | 6 |
| 2 | 34/F | HL | IIBx | Relapse | No | VEBEP × 8 | Mantle | No | 24 |
| 3 | 57/M | HL | IVB | Relapse | Yes | VEBEP × 8 | STNI | No | 36 |
| 4 | 32/M | HL | IBx | Relapse | No | MOPP/ABVD × 6 | Mediastinum | No | 18 |
| 5 | 42/F | HL | IIBx | Refractory | No | ABVD × 7 | — | No | 1 |
| 6 | 57/F | HL | IVAx | Refractory | Yes | EBVD × 8 | — | No | 1 |
| 7 | 45/F | HL | IVA | Relapse | No | ABVD × 8 | Para-aortic | No | 12 |
| 8 | 19/F | HL | IIB | Relapse | No | ABVD × 7 | Mantle | No | 12 |
| 9 | 60/F | FL | IVA | Relapse | Yes | Fludarabine × 6 DHAP × 1 | Para-aortic | No | 1 |
| 10 | 47/F | FL | IVA | Relapse | No | CVP × 8 2CdA × 7 | — | Yes | 1 |
| 11 | 59/M | DLBCL | IVA | Relapse | No | Fludarabine × 10 | — | No | 10 |
| 12 | 57/F | DLBCL | IVB | Relapse | No | CHOP × 6 | — | No | 8 |
| 13 | 67/M | MM | IIIA | PR | Yes | VAD × 2 DT-PACE × 1 | — | No | 1 |
| 14 | 52/M | t-AML | — | CR | No | BEP × 3 FLAG-Ida × 1 | Para-aortic | No | 2 |
| 15 | 53/F | t-AML | — | CR | No | MOPP/ABVD × 8 VEBEP × 8 CBDCA × 8 FLAG-Ida × 1 | STNI | Yes | 2 |
| 16 | 58/F | t-AML | — | CR | No | FLAG-Ida × 1 | STNI | Yes | 2 |
HL indicates Hodgkin lymphoma; EBVD, etoposide, BCNU, vincristine, dexamethasone; STNI, subtotal nodal irradiation; VEBEP, etoposide, epirubicin, bleomycin, cyclophosphamide, prednisone; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ABVD, adriamycin, bleomycin, vinblastine, dexamethasone; FL, follicular lymphoma; DHAP, cisplatin, cytarabine, dexamethasone; CVP, cyclophosphamide, vincristine, prednisone; 2CdA, cladribine; DLBCL, diffuse large B-cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MM, multiple mycloma; PR, partial remission; VAD, vincristine, doxorubicin, dexamethasone; DT-PACE, dexamethasone, thalidomide, cisplatin, cyclophosphamide, doxorubicin, etoposide; t-AML, therapy-related acute myeloid leukemia; CR, complete remission; BEP, bleomycin, etoposide, cisplatin; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin; CBDCA, carboplatin; STNI, subtotal nodal irradiation; and—, patient underwent no previous radiotherapy.